Drug Trial Radar · NCT07028801
Clinical Trial of Freeze-dried Human Rabies Vaccine (Human Diploid Cells)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,000
Actual
Start
Jul 30, 2025
Primary completion
Apr 8, 2026
Study completion Apr 10, 2026
Sponsor
- Lead sponsor
- Ningbo Rongan Biological Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 10 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The Phase 3 clinical trial of freeze-dried human rabies vaccine (human diploid cells) adopted a randomized, blinded, parallel control,non-inferiority design,and administered vaccines to participants aged 10 to 60 years with different immunization schedules (5-dose schedule group, two simple 4-dose schedule groups, and 2-1-1 schedule group) to evaluate the immunogenicity and safety of the vaccine.
Conditions
- Rabies
Interventions
Freeze-dried human rabies vaccine (human diploid cells)Biological
This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 5 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection. Receive 1 dose on day 0, 3, 7, 14 and 28, total 5 doses
Freeze-dried human rabies vaccine (human diploid cells)Biological
This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 4 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection. Receive 1 dose on day 0, 3, 7 and 14, total 4 doses
Freeze-dried human rabies vaccine (human diploid cells)Biological
This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 4 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection. Receive 1 dose on day 0, 3, 7 and 28, total 4 doses
Freeze-dried human rabies vaccine (human diploid cells)Biological
This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 4 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection. Receive 2 dose on day 0, 1 dose on day 7 and 21, total 4 doses
Freeze-dried human rabies vaccine (human diploid cells)Biological
This vaccine is produced by Chengdu Kanghua Biological Products Co., LTD Participants will be administered 5 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection Receive 1 dose on day 0, 3, 7, 14and 28, total 5 doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Antibody SCR for the 5-dose schedule group of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after the first dose
- Antibody GMC for the 5-dose schedule group of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after the first dose
- Antibody SCR for the simple 4-dose schedule group 1 of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after the first dose
- Antibody GMC for the simple 4-dose schedule group 1 of the trial vaccine and the 5-dose schedule of the control vaccineTime frame: 14 days after the first dose
- Antibody SCR for the simple 4-dose schedule group 2 of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after the first dose
- Antibody GMC for the simple 4-dose schedule group 2 of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after the first dose
- Antibody SCR for the 2-1-1 schedule group of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after the first dose
- Antibody GMC for the 2-1-1 schedule group of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after the first dose
- Antibody SCR for the 5-dose schedule group of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after full vaccination
- Antibody SCR for the simple 4-dose schedule group 1 of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after full vaccination
- Antibody SCR for the simple 4-dose schedule group 2 of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after full vaccination
- Antibody SCR for the 2-1-1 schedule group of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after full vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Provincial Center for Disease Control and Prevention
Zhengzhou, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.